Elizabeth Fox, MD

Elizabeth Fox, MD

Elizabeth Fox, MD, is an attending physician and head of Developmental Therapeutics at CHOP’s Cancer Center. She has specific expertise in early phase clinical trials.

Areas of Expertise: Liver tumors, Rare malignant solid tumors including neuroendocrine tumors (carcinoid tumors, pheochromocytoma/paraganglioma) or melanoma, Relapsed or refractory solid tumors
Locations: Main Campus
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)

Education and Training

Medical School

MD - Pennsylvania State University College of Medicine, Hershey, PA

Internship

Pediatrics - Strong Memorial Hospital, University of Rochester, Rochester, NY

Residency

Pediatrics - Strong Memorial Hospital, University of Rochester, Rochester, NY

Fellowship

Pediatric Hematology/ Oncology - Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD

Board Certification

Pediatric Hematology-Oncology

Graduate Degree

MS in Clinical Research - Duke University College of Medicine, Durham, NC

Titles and Academic Titles

Attending Physician

Head, Developmental Therapeutics, Division of Oncology

Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

Departments and Services

Publications

Papers

2016

DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP.  Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016 Apr 20;34(12):1368-75. doi: 10.1200/JCO.2015.65.4889. Epub 2016 Feb 16. 

2015

Kim A, Widemann BC, Krailo M, Jayaprakash N, Fox E, Weige BJ, Blaney SM. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Sep;62(9):1562-6. doi: 10.1002/pbc.25548. Epub 2015 Apr 27.

Lodish MB, Gkourogianni A, Bornstein E, Sinaii N, Fox E, Chuk M, Marcus L, Akshintala S, Balis F, Widemann B, and Stratakis CA. Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy. Int J Pediatr Endocrinol. 2015;2015(1):3.

57. Fox E, Widemann BC, Pastakia D Chen C,  Yang S, Cole D, Balis F. Pharmacokinetic and Pharmacodynamic study of tariquidar (XR9576) a P-glycoprotien inhibitor, in combination with doxorubicin, vinorelbine or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemotherapy and Pharmacology Cancer Chemother Pharmacol. 2015 Dec;76(6):1273-83. doi: 10.1007/s00280-015-2845-1. Epub 2015 Oct 20.

2014

Norris R, Moorthy G, Adamson PC, Fox E.  A liquid chromatography/tandem mass spectrometry method for determination of obatoclax in human plasma J Chromatogr B Analyt Technol Biomed Life Sci. 15;971:30-4, 2014.

Desai A, Fox E, Smith LM, Lim AP, Maris JM, Balis FM.  Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high risk neuroblastoma. Cancer Chemotherap Pharmacol (2014) 74(5):1047-55, 2014.

Himebauch AS, Nicolson SA, Sisko M, Moorthy G, Fuller S, Gaynor JW, Zuppa A, Fox E, Kilbaugh T.  Skeletal Muscle and Plasma Concentrations of Cefazolin during Cardiac Surgery in Infants J Thoracic Cardiovascular Surgery 148(6):2634-41,  2014.

Norris R, Shusterman S, Gore L, Muscal J, Macy M, Fox E, Berkowitz N, Buchbinder A, Bagatell R. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children, adolescents, and young adults with relapsed or refractory solid tumors.  Pediatric Blood and Cancer 61:17922-1797, 2014.

Widemann BC, Babovic-Vuksanovic D., Dombi E, Wolters PL, Goldman S, Martin S, Goodwin A., Goodspeed, W, Kieran, MW, Cohen B., Blaney SM., King A., Solomon J., Patronas N., Balis, FM., Fox, E, Steinberg SM., Packer RJ.  Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.  Pediatric Blood and Cancer 61(9) 1598-602, 2014

Widemann BC, Dombi E, Gilespie A, Wolters P, Belasco J, Goldman S, Korf B, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran M, Perentesis J, Reddy A, Wright J, Kim A, Steinberg S, Balis FM.  Phase II randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas Neuro Oncol. May;16(5):707-18, 2014.

Fox E, Mosse YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn CL, Adamson PC, London WB, Maris JM, Balis FM. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621) Pediatric Blood and Cancer 61(6) 990-6, 2014.

Bagatell R, Norris R, Ingle AM, Ahern CH, Voss S, Fox E, Little A, Weigel B, PA Adamson PA, Blaney SM Phase 1 Trial of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors:  A Children’s Oncology Group Study. Pediatr Blood Cancer. May;61(5):833-9, 2014.

Norris R, Adamson PC, Nguyen VT, Fox E. Preclinical Evaluation of the PARP Inhibitor, Olaparib, in Combination with Cytotoxic Chemotherapy in Pediatric Solid Tumors. Ped Blood Cancer Jan;61(1):145-50, 2014.

Abstracts

2016

DuBois  SG , Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J,  Lai H , Goodarzian F, Shimada H, Boucher N, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP. Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Advance in Neuroblastoma Research Cairns Australia, 2016.

Geoerger B, Fox E, Pappo AS, Oren MY, Marshall LV, Heath K, Diede SJ, Ebbinghaus S, Park JR. Phase 1/2 study of pembrolizumab (pembro) in children with advanced melanoma or a PD-L1-positive (PD-L1+) advanced, relapsed, or refractory solid tumor or lymphoma (KEYNOTE-051). American Society of Clinical Oncology, Chicago, IL, 2016.

DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen SG, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H,  Goodarzian F, Shimada H, Boucher N, Czarnecki S, Tsao-Wei DD, Matthay KK, Mosse YP. Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium American Society of Clinical Oncology, Chicago, IL, 2016.

Balis FM, Womer RB, Berg SL, Adamson PC, Fox E. Current approach and recommendations for standardized dosing of anticancer drugs in infants. American Society of Clinical Oncology, Chicago, IL, 2016.

Balis FM, Womer RB, Berg SL, Adamson PC, Fox E. Current approach and recommendations for standardized dosing of anticancer drugs in infants. American Society of Clinical Oncology, Chicago, IL, 2016.

Schafer E, Rau RE, Liu X, Minard CG, D'Adamo D, Scott R, Reyderman L, Martinez GMV, Fox E, Weigel B, Blaney S . A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children's Oncology Group Phase 1 Consortium study (ADVL1314). American Society of Clinical Oncology, Chicago, IL, 2016.

Minard CG, Seibel N, Berg SL, Fox E, Weigel BJ Impact of the pediatric central institutional review board (PedCIRB) in Children's Oncology Group Phase 1 Consortium dose escalation studies.  American Society of Clinical Oncology, Chicago, IL, 2016.

Sima,J. Moorthy G, Zuppa A, Fox E. Development and validation of a LC-MS/MS method for the simultaneous quantitation of carboplatin and etoposide in human plasma and ultrafiltrate. Am Society for Mass Spectrometry;  San Antonio,  TX 2016.

2015

Norris RE, Fox E, Reid JM, zRalya AT, Lui X, Minard C, Dahl J, Eubank R, Weigel B. Phase 1 Trial of Ortuxizumab (MORAb-004) in Children with Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Phase 1 Consortium Study (ADVL1213).  American Society of Clinical Oncology, Chicago, IL, 2015.

Lee A, Glade Bender G, Weigel B, Fox E, Huff A, Tada H, Blaney S, Langmuir P.  A Phase 2 Study of Pazopanib in Children, Adolescents, and Young Adults with Refractory Solid Tumors.  American Society of Clinical Oncology, Chicago, lL, 2015.

Cole PD, Metzger M, Drachtman RA, Horton TM, Lui X, Ahern C, Minard C, Fox E, Blaney S, Weigel B, Kelly K. AHOD1221: A Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children’s Oncology Group report.  American Society of Clinical Oncology, Chicago, IL 2015.

Greengard E, Mosse P, Ahern C, Minard C, Blaney S, Fox E, Weigel B.  A Phase 1 Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma: A Children’s Oncology group Phase 1 Consortium Study.  American Society Clinical Oncology, Chicago, IL 2015.

Akshintala S, Dombi E, Glod J, Fox E, Lodish M, Whitcomb P, Balis FM, Widemann BC.  Response and Resistance to the Receptor Tyrosine Kinase Inhibitor Vandetanib in Pediatric Patients with Medullary Thyroid Carcinoma.  American Society of Pediatric Hematology Oncology; Phoenix, AZ, 2015.

Fox E, Amodei K, Mattei P, Kolon T, Johnson A, Darge C, Balis FM.  Longitudinal assessment of renal function using cystatin C and functional MRI in children with newly diagnosed renal tumors. Cancer and the Kidney (c-kin) International, Brussels, Belgium, 2015.

2014

London LB, Bagatell R, Weigel B, Fox E, Van Ryn C, Naranjo A, Krailo MD, Ahern CH, Park JR; Historical gold standard for time-to-progression (TTP) and progression-free survival (PFS) from relapsed/refractory neuroblastoma modern era (2002-2014) patients. American Society of Clinical Oncology, Chicago, IL, 2014.

Fox E, Amodei K, Mattei P, Kolon T, Johnson A, Darge C, Balis FM.  Prospective assessment of renal function using cystatin C and functional MRI in children with newly diagnosed renal tumors American Society of Clinical Oncology, Chicago, 2014.

Meany HJ, Hinds PS, Bagatell R, Shusterman S, Widemann BC, Stern E, London WB, Kim A, Fox E, Rodriguez-Galindo C, Minturn JE, Dome J. Phase 1 Study of Sorafenib and Irinotecan in Pediatric Patients with Relapsed or Refractory Solid Tumors. American Society of Clinical Oncology, Chicago, IL, 2014.

Chuk M, Widemann B, Ahern C, Reid J, Fox E, Weigel B, Blaney SM. Cabozantinib, an oral inhibitor of tyrosine kinases including MET, VEGFR2 and RET, is approved for adults with progressive, metastatic medullary thyroid carcinoma (MTC).  We conducted a phase I and pharmacokinetic (PK) trial of cabozantinib in children with refractory solid tumors. American Society of Clinical Oncology, Chicago, IL, 2014.

Geller J,  Perentesis J, Ahern CH, Kudgus RA, Reid JM, Fox E,  Blaney M, Weigel BJ.  A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND#112603) in Children with Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study. American Society of Clinical Oncology, Chicago, IL, 2014.

DuBois SG, Mosse YP, Fox E, Reid J, Groshen S, Tsao-Wei D, Bagatell R, Maris J, Wagner L, Marachelian A, Matthay K. Phase I Study of the Aurora A Kinase Inhibitor MLN8237 with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma:  A Report from the New Approaches to Neuroblastoma Therapy (NANT) Consortium Advance in Neuroblastoma Cologne, Germany, 2014.

Books

Chapters

Fox E, Balis FM. Drug therapy in newborns and children. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, editors. Principles of clinical pharmacology. 2nd ed. Burlington: Academic Press; 2006.

Fox E, Adamson PC. Future trends in cancer chemotherapy. In: Voute PA, Barrett A, Stevens, MCG, editors. Cancer in children clinical management. 5th ed. New York: Oxford University Press; 2005.

Fox E, Adamson PC. Phase I trial design considerations in the pediatric population. In: Budman DR, Calvert AH, Rowinsky EK, editors. Handbook of anticancer drug development. Philadelphia: Lippincott Williams & Wilkins; 2003.

Fox E, Balis FM. Drug therapy in newborns and children. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, editors. Principles of clinical pharmacology. Burlington: Academic Press; 2001.

Posters and Presentations

Invited Lectures
2016

Fox E. 2016 ASPHO Workshop Moderator: Melanoma in Children and Adolescents. Minneapolis, MN; 2016 May 12. 

Fox E. Grand Rounds: Determining the Recommended Dose of Anticancer Therapy in Children and Adolescents. New York Medical College, Department of Pediatrics; 2016 Feb 26; Westchester, NY.

2015

Fox E. Determining the Recommended Dose of Anticancer Therapy in Children and Adolescents. Stanford University, Lucile Packard Children’s Hospital at Stanford; 2015 Oct 26; Palo Alto CA.

Fox E. FDA Mini-Symposium on Clinical Pharmacology Considerations in Pediatric Oncology Trials: Clinical pharmacology considerations in early phase clinical trials of targeted therapies. FDA; 2015 Jul 20;  White Oak Campus, MD.

Fox E. Continuing Medical Education and Outreach Seminar,  Updates in Pediatric Oncology: Skin Cancer Not So Fun in The Sun. The Children’s Hospital of Philadelphia; 2014-2015; Philadelphia, PA.

2014

Fox E. Invited Lecture: The Role of Pharmacology in Clinical Drug Development in Oncology. Boston Children’s Hospital and Dana Farber Cancer Institute; 2014; Boston, MA 

Fox E. Visiting Faculty, Pediatric Oncology and Molecular Pharmacology and Experimental Therapeutics. Role of Clinical Pharmacology in Pediatric Oncology Drug Development. Mayo Clinic; 2014; Rochester, MN.

Fox E. Visiting Professor. Drug Distribution and Pharmacokinetics in Pediatrics. Introduction to Principles of Pharmacokinetics Course (T32 and Graduate Program Clinical Pharmacology): Mayo Clinic, Rochester, MN; 2014; Rochester, MN.

Awards and Honors

2008, NIH Award of Merit for the Transition of Carboxypeptidase Treatment Program (group award)

2006, NIH Director’s Award of Merit for Contributions to Clinical Development of Treatment for Childhood Cancer (individual award)

2002, ASCO Merit Award

2000, AACR - Glaxo Wellcome Oncology Scholar Award for Promising Clinical/Translational Research

1999, NCI Fellowship Training Award

1995, Feigin Scholar, Texas Children’s Hospital

1991, Shapiro Scholar, Dept. Pediatrics, University of Rochester

Editorial and Academic Positions

Editorial positions

Editorial boards

2007-present, Associate Editor, Journal of the National Cancer Institute

Scientific reviewer

Blood
Cancer Chemotherapy & Pharmacology
Cancer Research
Clinical Cancer Research
Journal of Clinical Oncology
Journal of the National Cancer Institute
Journal of Pediatric Hematology & Oncology
Journal of Pharmacology & Experimental Therapeutics
Pediatric Blood & Cancer

Academic and Institutional Committees

2015-2016, CHOP Oncology Clinical Research Task Force

2012-present, COG Chemotherapy Standardization Task Force

2010-present, CHOP Division of Oncology Pediatric Protocol Review Committee

2010-2015, CHOP Annual Poster Day Judge: Patient Oriented Research

2010-present, CHOP IND/IDE Protocol Review Committee

Children's Oncology Group Study Committees

  • ADVL1411 Phase 1 BMN673 +temozolomide (member)
  • ADVL1412 Phase 1-2 Nivolumab ±Ipilimumab (member)
  • ADVL1414 Phase 1 Selinexor (member)
  • ADVl1416 Phase 1 Ramucirumab (member)
  • ADVL1312 Phase 1 Study of AZD1775+ irinotecan (Protocol Vice Chair)
  • ADVL1314 Phase 1 Eribulin (member)
  • ADVL1315 Phase 1 Axitinib (member)
  • ANBL1232 Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma (member)
  • ADVL1212 Phase 1 Study of Crizotinib + chemotherapy (member)
  • ADVL1213 Phase 1 TEM-1 antibody MORAb-004 (Protocol Vice Chair)
  • ADVL1217 Phase 1 Study of AZD1775 + radiation in DIPG (member)
  • AAML1031 Phase 3 trial of Bortezemab and sorafenib in AML (member)
  • ADVL0912 Phase 1-2 Study of Crizotinib (member)

Leadership and Memberships

Memberships in Professional Organizations

2002-present, Children’s Oncology Group

1998-present, American Society of Clinical Oncology

1997-present, American Association for Cancer Research